---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Wed, Jul 16, 2008 at 9:21 AM
Subject: Noninvasive Tracer Techniques to Characterize Angiogenesis.
To: mesothelioma77@gmail.com
[1]Handb Exp Pharmacol. 2008; 185/2: 323-339
Haubner R
Great efforts are being made to develop antiangiogenesis drugs for treatment of cancer as well as other diseases. Some of the compounds are already in clinical trials. Imaging techniques allowing noninvasive monitoring of corresponding molecular processes can provide helpful information for planning and controlling corresponding therapeutic approaches but will also be of interest for basic science. Current nuclear medicine techniques focus on the development of tracer targeting the vascular endothelial growth factor (VEGF) system, matrix metalloproteinases (MMP), the ED-B domain of a fibronectin isoform, and the integrin alphavbeta3. In this chapter, the recent tracer developments as well as the preclinical and the clinical evaluations are summarized and the potential of the different approaches to characterize angiogenesis are discussed.
___
Source: http://www.hubmed.org/display.cgi?uids=18626609
--
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Wed, Jul 16, 2008 at 9:21 AM
Subject: Noninvasive Tracer Techniques to Characterize Angiogenesis.
To: mesothelioma77@gmail.com
[1]Handb Exp Pharmacol. 2008; 185/2: 323-339
Haubner R
Great efforts are being made to develop antiangiogenesis drugs for treatment of cancer as well as other diseases. Some of the compounds are already in clinical trials. Imaging techniques allowing noninvasive monitoring of corresponding molecular processes can provide helpful information for planning and controlling corresponding therapeutic approaches but will also be of interest for basic science. Current nuclear medicine techniques focus on the development of tracer targeting the vascular endothelial growth factor (VEGF) system, matrix metalloproteinases (MMP), the ED-B domain of a fibronectin isoform, and the integrin alphavbeta3. In this chapter, the recent tracer developments as well as the preclinical and the clinical evaluations are summarized and the potential of the different approaches to characterize angiogenesis are discussed.
___
Source: http://www.hubmed.org/display.cgi?uids=18626609
--
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc